回盛生物
(300871)
| 流通市值：44.45亿 | | | 总市值：44.45亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 209,053,643.59 | 236,264,147.13 | 271,699,911.85 | 326,144,663.23 |
| 交易性金融资产 | 283,806,091.49 | 277,919,747.63 | 297,960,024.03 | 200,965,615.92 |
| 应收票据及应收账款 | 456,645,031.85 | 447,388,057.55 | 457,004,466.25 | 430,153,031.26 |
| 其中：应收票据 | 65,176,331.85 | 56,830,794.89 | 41,957,386.1 | 61,785,555.46 |
| 应收账款 | 391,468,700 | 390,557,262.66 | 415,047,080.15 | 368,367,475.8 |
| 应收款项融资 | 21,807,663.83 | 19,804,849.04 | 17,736,482.31 | 16,115,591.14 |
| 预付款项 | 28,338,997.82 | 25,974,010.17 | 31,383,544.9 | 71,014,168.55 |
| 其他应收款合计 | 10,735,900.11 | 11,306,453.79 | 11,487,346.9 | 8,087,668.77 |
| 存货 | 254,459,287.83 | 245,430,574.11 | 244,328,189.32 | 248,164,158.72 |
| 其他流动资产 | 5,487,192.65 | 3,556,879.6 | 14,409,257.95 | 11,940,519.63 |
| 流动资产合计 | 1,270,333,809.17 | 1,267,644,719.02 | 1,346,009,223.51 | 1,312,585,417.22 |
| 非流动资产: | | | | |
| 投资性房地产 | 13,483,194.26 | 13,714,004.61 | 11,290,219.97 | 11,483,231.64 |
| 固定资产 | 1,508,700,812.94 | 1,535,052,937.56 | 1,505,027,290.5 | 1,525,198,068.46 |
| 在建工程 | 20,460,529.89 | 12,432,281.44 | 39,754,942.11 | 18,145,020.03 |
| 无形资产 | 111,460,171.33 | 112,445,810.36 | 113,541,296.23 | 114,441,743.87 |
| 商誉 | 670,682.2 | - | - | - |
| 长期待摊费用 | 1,034,540.47 | 1,607,430.7 | 1,732,421.77 | 1,898,710.71 |
| 递延所得税资产 | 21,676,070.4 | 21,068,926.5 | 25,045,333.41 | 27,168,464.42 |
| 其他非流动资产 | 10,191,949.78 | 4,031,302.58 | 3,749,048.58 | 3,762,208.67 |
| 非流动资产合计 | 1,687,677,951.27 | 1,700,352,693.75 | 1,700,140,552.57 | 1,702,097,447.8 |
| 资产总计 | 2,958,011,760.44 | 2,967,997,412.77 | 3,046,149,776.08 | 3,014,682,865.02 |
| 流动负债: | | | | |
| 短期借款 | 276,091,140.43 | 294,908,133.89 | 355,689,151 | 316,784,375.11 |
| 应付票据及应付账款 | 318,004,731.96 | 383,423,852.52 | 450,632,356.35 | 507,302,745.13 |
| 其中：应付票据 | 117,451,950.7 | 170,373,547.89 | 226,488,758.46 | 283,877,725.77 |
| 应付账款 | 200,552,781.26 | 213,050,304.63 | 224,143,597.89 | 223,425,019.36 |
| 预收款项 | - | - | - | 10,200 |
| 合同负债 | 17,224,445.72 | 16,130,342.13 | 15,520,434.9 | 13,463,235.54 |
| 应付职工薪酬 | 24,078,096.77 | 19,061,870.49 | 13,792,846.63 | 20,259,817.66 |
| 应交税费 | 19,924,558.62 | 16,428,141.82 | 9,545,304.92 | 2,820,565.6 |
| 其他应付款合计 | 31,061,618.35 | 23,859,973.07 | 21,974,097.82 | 21,835,179.44 |
| 一年内到期的非流动负债 | 18,024,861.11 | 20,026,305.56 | 46,012,507.03 | 16,317,355.62 |
| 其他流动负债 | 40,756,139.72 | 34,479,062.62 | 34,927,318.21 | 24,521,628.73 |
| 流动负债合计 | 745,165,592.68 | 808,317,682.1 | 948,094,016.86 | 923,315,102.83 |
| 非流动负债: | | | | |
| 长期借款 | 35,514,652 | 35,514,652 | 17,972,694 | 59,062,791.67 |
| 应付债券 | - | - | 428,386,493.14 | 496,391,884.2 |
| 递延收益 | 54,381,705.52 | 54,754,750.93 | 56,549,181.88 | 58,343,612.83 |
| 递延所得税负债 | 2,876,166.4 | 2,961,976.8 | 9,118,843.69 | 11,366,356.63 |
| 其他非流动负债 | 2,000,000 | 1,000,000 | 1,000,000 | 1,000,000 |
| 非流动负债合计 | 94,772,523.92 | 94,231,379.73 | 513,027,212.71 | 626,164,645.33 |
| 负债合计 | 839,938,116.6 | 902,549,061.83 | 1,461,121,229.57 | 1,549,479,748.16 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 202,332,557 | 202,332,557 | 171,146,882 | 165,765,635 |
| 其他权益工具 | - | - | 85,377,429.15 | 100,013,662.44 |
| 资本公积 | 1,451,114,795.39 | 1,450,388,737.42 | 966,822,369.81 | 880,629,959.53 |
| 减:库存股 | 17,780,284.68 | 17,433,518.28 | 18,141,290.28 | 17,571,722.28 |
| 其他综合收益 | -3,785,065.99 | -2,641,643.15 | -1,662,134.21 | -1,474,241.12 |
| 盈余公积 | 52,979,506 | 52,979,506 | 52,979,506 | 52,979,506 |
| 未分配利润 | 423,531,005.49 | 372,964,159.44 | 321,730,983.86 | 277,234,024.45 |
| 归属于母公司股东权益合计 | 2,108,392,513.21 | 2,058,589,798.43 | 1,578,253,746.33 | 1,457,576,824.02 |
| 少数股东权益 | 9,681,130.63 | 6,858,552.51 | 6,774,800.18 | 7,626,292.84 |
| 股东权益合计 | 2,118,073,643.84 | 2,065,448,350.94 | 1,585,028,546.51 | 1,465,203,116.86 |
| 负债和股东权益合计 | 2,958,011,760.44 | 2,967,997,412.77 | 3,046,149,776.08 | 3,014,682,865.02 |
| 公告日期 | 2025-10-28 | 2025-08-06 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |